Proactiveinvestors recommends

Additional Information

Market:	ASX
Sector:	Pharma & Biotech
EPIC:	QRX
Latest Price:	1.64 (2.82% )
52-week High:	2.39
52-week Low:	1.06
Market Cap:	236.46M

1 year chart

1 day chart

QRxPharma

QRxPharma Limited (ASX: QRX) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders.

The Company’s lead products comprise a patented combination of existing drugs, with a well-defined path to regulatory approval and sales. The Company’s preclinical and clinical pipeline includes other technologies in the fields of neurodegenerative disease and venomics.

Australian Ethical Investments lodges substantial shareholder notice with QRxPharma

Wednesday, January 06, 2010

QRxPharma (ASX: QRX; OTCQX: QRXPY) has received a notice of substantial shareholder from Australian Ethical Investment fund managers.

The fund became a substantial holder on 18 December 2009, acquiring 5.279m shares in QRx at $0.80 per share.

In November 2009, QRxPharma completed an underwritten institutional placement at A$0.80 per share, raising A$8.0 million which was significantly oversubscribed.

Proceeds from the Placement and Rights Issue (which in total raised raised A$21.6 million) will be used for funding
the Phase 3 drug development and expenditure programme for its MoxDuo™ IR (immediate release dual opioid) product.

This includes the lodgement of a New Drug Application with the US Food and Drug Administration in 2010, and for additional working capital purposes.

QRxPharma plans for launch of MoxDuo™ IR in the US marketplace in 2011.

MoxDuo™ IR is intended for the management of moderate to severe acute pain. QRxPharma’s product pipeline also includes intravenous (IV) and controlled release (CR) formulations which are in earlier stages of clinical development.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.